Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Glioma Diagnosis Treatment Market

ID: MRFR/Pharma/17379-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026

US Glioma Diagnosis and Treatment Market Research Report By Type (Primary Tumors, Secondary Tumors), By Diagnosis (Neurological Exam, CT Scan, MRI, PET Scan, Biopsy, Molecular Testing, EEG, Others), By Treatment (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy), By Grade (Low Grade Glioma, High Grade Glioma, Recurrent High Grade Glioma), By Location (Supratentorial, Infratentorial) and By End User (Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Glioma Diagnosis Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Type (USD Million)
  49.     4.1.1 Primary Tumors
  50.     4.1.2 Secondary Tumors
  51.   4.2 Construction, BY Diagnosis (USD Million)
  52.     4.2.1 Neurological Exam
  53.     4.2.2 CT Scan
  54.     4.2.3 MRI
  55.     4.2.4 PET Scan
  56.     4.2.5 Biopsy
  57.     4.2.6 Molecular Testing
  58.     4.2.7 EEG
  59.     4.2.8 Others
  60.   4.3 Construction, BY Treatment (USD Million)
  61.     4.3.1 Surgery
  62.     4.3.2 Chemotherapy
  63.     4.3.3 Radiation Therapy
  64.     4.3.4 Immunotherapy
  65.     4.3.5 Targeted Therapy
  66.   4.4 Construction, BY Grade (USD Million)
  67.     4.4.1 Low Grade Glioma
  68.     4.4.2 High Grade Glioma
  69.     4.4.3 Recurrent High Grade Glioma
  70.   4.5 Construction, BY Location (USD Million)
  71.     4.5.1 Supratentorial
  72.     4.5.2 Infratentorial
  73.   4.6 Construction, BY End User (USD Million)
  74.     4.6.1 Hospitals & Clinics
  75.     4.6.2 Diagnostic Centers
  76.     4.6.3 Medical Research Centers
  77.     4.6.4 Others
  78. 5 SECTION V: COMPETITIVE ANALYSIS
  79.   5.1 Competitive Landscape
  80.     5.1.1 Overview
  81.     5.1.2 Competitive Analysis
  82.     5.1.3 Market share Analysis
  83.     5.1.4 Major Growth Strategy in the Construction
  84.     5.1.5 Competitive Benchmarking
  85.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  86.     5.1.7 Key developments and growth strategies
  87.       5.1.7.1 New Product Launch/Service Deployment
  88.       5.1.7.2 Merger & Acquisitions
  89.       5.1.7.3 Joint Ventures
  90.     5.1.8 Major Players Financial Matrix
  91.       5.1.8.1 Sales and Operating Income
  92.       5.1.8.2 Major Players R&D Expenditure. 2023
  93.   5.2 Company Profiles
  94.     5.2.1 Roche (CH)
  95.       5.2.1.1 Financial Overview
  96.       5.2.1.2 Products Offered
  97.       5.2.1.3 Key Developments
  98.       5.2.1.4 SWOT Analysis
  99.       5.2.1.5 Key Strategies
  100.     5.2.2 Novartis (CH)
  101.       5.2.2.1 Financial Overview
  102.       5.2.2.2 Products Offered
  103.       5.2.2.3 Key Developments
  104.       5.2.2.4 SWOT Analysis
  105.       5.2.2.5 Key Strategies
  106.     5.2.3 Merck (DE)
  107.       5.2.3.1 Financial Overview
  108.       5.2.3.2 Products Offered
  109.       5.2.3.3 Key Developments
  110.       5.2.3.4 SWOT Analysis
  111.       5.2.3.5 Key Strategies
  112.     5.2.4 Bristol-Myers Squibb (US)
  113.       5.2.4.1 Financial Overview
  114.       5.2.4.2 Products Offered
  115.       5.2.4.3 Key Developments
  116.       5.2.4.4 SWOT Analysis
  117.       5.2.4.5 Key Strategies
  118.     5.2.5 Eli Lilly (US)
  119.       5.2.5.1 Financial Overview
  120.       5.2.5.2 Products Offered
  121.       5.2.5.3 Key Developments
  122.       5.2.5.4 SWOT Analysis
  123.       5.2.5.5 Key Strategies
  124.     5.2.6 Amgen (US)
  125.       5.2.6.1 Financial Overview
  126.       5.2.6.2 Products Offered
  127.       5.2.6.3 Key Developments
  128.       5.2.6.4 SWOT Analysis
  129.       5.2.6.5 Key Strategies
  130.     5.2.7 AstraZeneca (GB)
  131.       5.2.7.1 Financial Overview
  132.       5.2.7.2 Products Offered
  133.       5.2.7.3 Key Developments
  134.       5.2.7.4 SWOT Analysis
  135.       5.2.7.5 Key Strategies
  136.     5.2.8 Pfizer (US)
  137.       5.2.8.1 Financial Overview
  138.       5.2.8.2 Products Offered
  139.       5.2.8.3 Key Developments
  140.       5.2.8.4 SWOT Analysis
  141.       5.2.8.5 Key Strategies
  142.     5.2.9 Bayer (DE)
  143.       5.2.9.1 Financial Overview
  144.       5.2.9.2 Products Offered
  145.       5.2.9.3 Key Developments
  146.       5.2.9.4 SWOT Analysis
  147.       5.2.9.5 Key Strategies
  148.   5.3 Appendix
  149.     5.3.1 References
  150.     5.3.2 Related Reports
  151. 6 LIST OF FIGURES
  152.   6.1 MARKET SYNOPSIS
  153.   6.2 US MARKET ANALYSIS BY TYPE
  154.   6.3 US MARKET ANALYSIS BY DIAGNOSIS
  155.   6.4 US MARKET ANALYSIS BY TREATMENT
  156.   6.5 US MARKET ANALYSIS BY GRADE
  157.   6.6 US MARKET ANALYSIS BY LOCATION
  158.   6.7 US MARKET ANALYSIS BY END USER
  159.   6.8 KEY BUYING CRITERIA OF CONSTRUCTION
  160.   6.9 RESEARCH PROCESS OF MRFR
  161.   6.10 DRO ANALYSIS OF CONSTRUCTION
  162.   6.11 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  163.   6.12 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  164.   6.13 SUPPLY / VALUE CHAIN: CONSTRUCTION
  165.   6.14 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
  166.   6.15 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
  167.   6.16 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
  168.   6.17 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
  169.   6.18 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
  170.   6.19 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
  171.   6.20 CONSTRUCTION, BY GRADE, 2024 (% SHARE)
  172.   6.21 CONSTRUCTION, BY GRADE, 2024 TO 2035 (USD Million)
  173.   6.22 CONSTRUCTION, BY LOCATION, 2024 (% SHARE)
  174.   6.23 CONSTRUCTION, BY LOCATION, 2024 TO 2035 (USD Million)
  175.   6.24 CONSTRUCTION, BY END USER, 2024 (% SHARE)
  176.   6.25 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
  177.   6.26 BENCHMARKING OF MAJOR COMPETITORS
  178. 7 LIST OF TABLES
  179.   7.1 LIST OF ASSUMPTIONS
  180.     7.1.1
  181.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  182.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  183.     7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  184.     7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  185.     7.2.4 BY GRADE, 2025-2035 (USD Million)
  186.     7.2.5 BY LOCATION, 2025-2035 (USD Million)
  187.     7.2.6 BY END USER, 2025-2035 (USD Million)
  188.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  189.     7.3.1
  190.   7.4 ACQUISITION/PARTNERSHIP
  191.     7.4.1

US Construction Market Segmentation

Construction By Type (USD Million, 2025-2035)

  • Primary Tumors
  • Secondary Tumors

Construction By Diagnosis (USD Million, 2025-2035)

  • Neurological Exam
  • CT Scan
  • MRI
  • PET Scan
  • Biopsy
  • Molecular Testing
  • EEG
  • Others

Construction By Treatment (USD Million, 2025-2035)

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy

Construction By Grade (USD Million, 2025-2035)

  • Low Grade Glioma
  • High Grade Glioma
  • Recurrent High Grade Glioma

Construction By Location (USD Million, 2025-2035)

  • Supratentorial
  • Infratentorial

Construction By End User (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Medical Research Centers
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓